Abstract:One of the major applications of generative models for drug discovery targets the lead-optimization phase. During the optimization of a lead series, it is common to have scaffold constraints imposed on the structure of the molecules designed. Without enforcing such constraints, the probability of generating molecules with the required scaffold is extremely low and hinders the practicality of generative models for de novo drug design. To tackle this issue, we introduce a new algorithm, named SAMOA (Scaffold Constrained Molecular Generation), to perform scaffold-constrained in silico molecular design. We build on the well-known SMILES-based Recurrent Neural Network (RNN) generative model, with a modified sampling procedure to achieve scaffold-constrained generation. We directly benefit from the associated reinforcement learning methods, allowing to design molecules optimized for different properties while exploring only the relevant chemical space. We showcase the method's ability to perform scaffold-constrained generation on various tasks: designing novel molecules around scaffolds extracted from SureChEMBL chemical series, generating novel active molecules on the Dopamine Receptor D2 (DRD2) target, and finally, designing predicted actives on the MMP-12 series, an industrial lead-optimization project.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01015?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01015</a>.Availability of data used to train models and run experiments, algorithmic description of naive policy masking (Algorithm S1), algorithmic description of hill-climbing (Algorithm S2), examples of molecules obtained after sampling the core of fexofenadine (Figure S1 for sampled molecules, Figure S2 for the original molecule), examples of molecules obtained after replacing the ring system of fexofenadine (Figure S3), distributions of ClogP, Molecular Weight, QED and SAS for reference molecules, molecules where a branched decoration was sampled, and molecules where the core was sampled (Figure S4), the 17 validation scaffolds from SureChEMBL (Figure S5), histograms of Tanimoto similarities between generated molecules for each of the DRD2 scaffolds (Figure S6), and unicity of sampled decorations for each open positions of the DRD2 scaffolds (Figure S7) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01015/suppl_file/ci0c01015_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Development of scoring-assisted generative exploration (SAGE) and its application to dual inhibitor design for acetylcholinesterase and monoamine oxidase B

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

Combining de novo molecular design with semiempirical protein-ligand binding free energy calculation

Human-in-the-loop assisted de novo molecular design

De novo generation of dual-target ligands using adversarial training and reinforcement learning

De novo drug design by iterative multiobjective deep reinforcement learning with graph-based molecular quality assessment

Structure-Based de Novo Molecular Generator Combined with Artificial Intelligence and Docking Simulations

Modern hit-finding with structure-guided de novo design: identification of novel nanomolar A2A receptor ligands using reinforcement learning

Generative Active Learning for the Search of Small-molecule Protein Binders

De Novo Structure-Based Drug Design Using Deep Learning

Scaffold-Constrained Molecular Generation

Modern hit-finding with structure-guided de novo design: identification of novel nanomolar adenosine A2A receptor ligands using reinforcement learning

Structure-based <i>de novo</i> drug design using 3D deep generative models

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

Molecular Design in Synthetically Accessible Chemical Space via Deep Reinforcement Learning

Multi-view deep learning based molecule design and structural optimization accelerates the SARS-CoV-2 inhibitor discovery

Molecular De Novo Design through Deep Reinforcement Learning

Deep Lead Optimization: Leveraging Generative AI for Structural Modification

Faster and more diverse de novo molecular optimization with double-loop reinforcement learning using augmented SMILES

De novo design of protein target specific scaffold-based Inhibitors via Reinforcement Learning

De Novo Drug Design by Multi-Objective Path Consistency Learning with Beam A∗ Search